Caixa Capital Risc leads Omnia Molecular round
Caixa Capital Risc, the private equity arm of La Caixa, has led a second round of funding for Barcelona-based biotech firm Omnia Molecular.
A total of €2.1m has been invested, of which La Caixa contributed just under €1m, while the company's founders and new management team injected €700,000 together with government-backed innovation agency ENISA.
Omnia founder Lluís Ribas remains the largest shareholder.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Susannah Birkwood on +44 20 7004 7524 or susannah.birkwood@incisivemedia.com
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








